Salesforce.com (CRM) Announces Annual Stockholders Meeting

Intellicheck Mobilisa (IDN) Receives Contract Worth $1M

Intellicheck Mobilisa, Inc. (NYSE Amex: IDN), a leading technology company specializing in wireless and identity systems, announced today that a seaport has purchased the Company’s IM2700 mobile Transportation Worker Identity Credential (TWIC) reader system. The contract, valued at $1 million, is the largest single TWIC sale in the Company’s history.

Steve Williams, Chief Executive Officer of Intellicheck Mobilisa, said, “This is the largest TWIC sale we have made to one facility and a market we’ve been creating and leading. The port wanted to increase their security efforts in order to meet the new security requirements associated with the use of TWIC cards. Our IM2700 TWIC reader was a natural addition to their security procedures.”

The TWIC program is an initiative of the Transportation Security Administration and U.S. Coast Guard to provide tamper-resistant biometric identification cards to port facility workers. TWIC cards have become a mandatory requirement for access to all U.S. ports as of April 15, 2009. Intellicheck Mobilisa’s TWIC reader handheld device is used to validate TWIC cards. The company believes such a universal reader will ultimately be needed at each of the more than 175 seaports in the U.S. Intellicheck Mobilisa’s TWIC reader is currently in use at major port facilities in California, Massachusetts, New Jersey, Texas and the State of Washington.

About Intellicheck Mobilisa

Intellicheck Mobilisa (ICMOBIL) is a leading technology company that is engaged in developing and marketing wireless technology and identity systems for various applications, including mobile and handheld access control and security systems for the government, military and commercial markets. ICMOBIL’s products include the Fugitive Finder system, an advanced ID card access control product currently protecting approximately 100 military and federal locations; ID Check, a patented technology that instantly reads, analyzes, and verifies encoded data in magnetic stripes and barcodes on government-issued IDs from U.S. and Canadian jurisdictions, designed to improve the Customer Experience for the financial, hospitality and retail sectors; and Aegeus, a wireless security buoy system for the government, military and oil industry.

For more news and information on ICMOBIL, please visit www.icmobil.com.

YM BioSciences (YMI) Reports Operational and Financial Results for the Third Quarter

Goldfield (GV) Announces Sharply Improved First Quarter Results

MELBOURNE, Fla., May 11, 2012 /PRNewswire/ — The Goldfield Corporation (NYSE Amex: GV) today announced continued improved results for the three months ended March 31, 2012. The Goldfield Corporation is a leading provider of electrical construction services in the Southeast with operations throughout much of the United States. Goldfield is also engaged, to a much lesser extent, in real estate development activities on the east coast of Florida.

Revenue for the three months ended March 31, 2012 nearly doubled, increasing to $17.7 million from $8.9 million in the comparable prior year period. This increase was attributable to higher electrical construction revenue.

Because of improved results in the electrical construction segment, the Company’s operating income for the three months ended March 31, 2012 increased to $2.7 million from an operating loss of $1,000 in the same prior year period.

For the three months ended March 31, 2012, the electrical construction segment’s operating results showed significant improvement, with revenue of $17.1 million and operating income of $3.3 million, compared to revenue of $8.2 million and operating income of $328,000 in the prior year. This increase in revenue was largely attributable to an increase in demand for our electrical construction services, particularly our transmission work, as a result of our expansion efforts during 2010 and 2011. As previously announced in February of 2012, the Company’s electrical construction segment was awarded a $52.0 million transmission line construction contract as part of the Competitive Renewable Energy Zones (”CREZ”) projects. Construction of the CREZ project commenced last month, and is currently scheduled to be completed on August 31, 2013. Our results for the first quarter did not include any revenue from this project.

For the three months ended March 31, 2012, the real estate development segment had revenue of $634,000 and operating income of $124,000, compared to revenue of $766,000 and operating income of $225,000, respectively, for 2011. We currently have no condominium projects under construction, and only have one unit remaining unsold from our Pineapple House project.

Net income for the three months ended March 31, 2012 was $2.7 million, or $0.10 per share, compared to a net loss of $11,000, or ($0.00) net loss per share, in the comparable prior year period.

John H. Sottile, Goldfield’s President and Chief Executive Officer stated, “The prospects for our electrical construction business are brighter today than at any time in recent history. Our backlog at March 31, 2012 was $70.6 million, up from $6.2 million at March 31st last year.” Mr. Sottile also added, “We believe that our recent expansion into Texas and our new CREZ project will provide a good opportunity for further growth in this region.”

About Goldfield

Goldfield is a leading provider of electrical construction and maintenance services in the energy infrastructure industry throughout much of the United States. The company specializes in installing and maintaining electrical transmission lines for a wide range of electric utilities. Goldfield is also involved, to a much lesser extent, in real estate development activities on Florida’s east coast.

For additional information on our first quarter results, please refer to our Quarterly Report on Form 10-Q being filed with the Securities and Exchange Commission and visit the Company’s website at http://www.goldfieldcorp.com.

This press release includes forward-looking statements based on our current expectations. Our actual results may differ materially from what we currently expect. Factors that may affect the results of our electrical construction operations include, among others: the level of construction activities by public utilities; the timing and duration of construction projects for which we are engaged; our ability to estimate accurately with respect to fixed price construction contracts; and heightened competition in the electrical construction field, including intensification of price competition. Factors that may affect the results of our real estate development operations include, among others: the continued weakness in the Florida real estate market; the level of consumer confidence; our ability to acquire land; increases in interest rates and availability of mortgage financing to our buyers; and increases in construction and homeowner insurance and the availability of insurance. Factors that may affect the results of all of our operations include, among others: adverse weather; natural disasters; effects of climate changes; changes in generally accepted accounting principles; ability to obtain necessary permits from regulatory agencies; our ability to maintain or increase historical revenue and profit margins; general economic conditions, both nationally and in our region; adverse legislation or regulations; availability of skilled construction labor and materials, and material increases in labor and material costs; and our ability to obtain additional and/or renew financing. Other important factors which could cause our actual results to differ materially from the forward-looking statements in this press release are detailed in the Company’s Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operation sections of our Annual Report on Form 10-K and Goldfield’s other filings with the Securities and Exchange Commission, which are available on Goldfield’s website: http://www.goldfieldcorp.com.

For further information, please contact:
The Goldfield Corporation
Phone: (321) 724-1700
Email: investorrelations@goldfieldcorp.com

Wowjoint Holdings Limited (BWOW) Signs Contract with Titan Peru S.A.C.

BEIJING, May 11, 2012 /PRNewswire-Asia/ — Wowjoint Holdings Limited (”Wowjoint,” or the “Company”) (Nasdaq: BWOW, BWOWU, BWOWW), China’s innovative infrastructure solutions provider of customized heavy duty lifting and carrying machinery, today announced it entered into an agreement to provide a tire gantry to a Peruvian company.

The agreement is with Titan Peru S.A.C., an import/export company in the construction industry, for a 50 ton Rubber Tire Gantry. The equipment is used for transporting precast concrete beams from the yard to the project site. The Company has started production and received 30% of the contract price as an advance payment. This is an initial contract with Titan Peru and we expect to have future contracts to export other Wowjoint products to Peru.

“We are pleased to have another new customer and to continue our International expansion with our first sale into South America,” Mr. Yabin Liu, Chief Executive Officer of Wowjoint stated. “Our sales team has continued to focus on our expansion into new markets and we’re pleased to see the progress we’ve made with the recent agreement with customers in Malaysia and now in Peru. Wowjoint has been successful in developing a sales team and business network covering East Asia, Southeast Asia, Europe, the Middle East, North American and South America. We are excited about the opportunities we have in these new markets.”

About Wowjoint Holdings Limited

Wowjoint is a leading provider of customized heavy duty lifting and carrying machinery used in large scale infrastructure projects such as railway, highway and bridge construction. Wowjoint’s main product lines include launching gantries, tyre trolleys, special carriers, marine hoists and special purpose equipment. The Company’s innovative design capabilities have resulted in patent grants and proprietary products. Wowjoint believes it is well-positioned to benefit directly from China’s rapid infrastructure development by leveraging its extensive operational experience and long-term relationships with established blue chip customers. Information on Wowjoint’s products and other relevant information are available on its website at http://www.wowjoint.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Wowjoint undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after the date of this communication. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this communication. All forward-looking statements are qualified in their entirety by this cautionary statement. All subsequent written and oral forward-looking statements concerning Wowjoint or other matters and attributable to Wowjoint or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Wowjoint does not undertake any obligation to update any forward-looking statement, whether written or oral, relating to the matters discussed in this news release.

For additional information contact:

Wowjoint Holdings:
Aubrye Foote, Vice President Investor Relations
Tel: +1-530-475-2793
Email: aubrye@wowjoint.com
Website: www.wowjoint.com

Tengion Provides Business Update and Reports Q1 2012 Financial Results

NOVAVAX (NVAX) Reports First Quarter 2012 Financial Results

ROCKVILLE, Md., May 4, 2012 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq:NVAX) today announced its financial results for the first quarter ended March 31, 2012.

The company reported a net loss of $7.3 million, or $0.06 per share, for the first quarter of 2012, compared to a net loss of $7.5 million, or $0.07 per share, for the first quarter of 2011. The company had significantly higher revenue in the first quarter of 2012 of $4.6 million as compared to $0.8 million for the same period in 2011, due primarily to revenue under the contract with the U.S. Department of Health and Human Services’ Office of Biomedical Advanced Research and Development Authority (HHS BARDA). In conjunction with the increased HHS BARDA revenue, the cost of contract revenue increased to $3.8 million in the first quarter of 2012 as compared to $0.3 million for the same period in 2011. In addition, research and development expenses remained flat year-over-year at $5.1 million.

The increase in cost of contract revenue reflects a company decision to conduct the current Phase II dose-ranging clinical trial in Australia under its existing U.S. investigational new drug application (”IND”) for its trivalent seasonal influenza vaccine candidate as opposed to waiting to conduct the trial under a new IND for its quadrivalent vaccine candidate. The company will record the outside clinical trial costs as cost of contract revenue until it submits the data from the trial for FDA review, expected in the second half of 2012. The outside clinical trial costs for this trial will be submitted for reimbursement to HHS BARDA and recorded as revenue by the company following its submission of the data to the quadrivalent IND. The financial impact of this delay in revenue recognition is based on this trial’s outside clinical trial costs that are expected to total approximately $3.1 million, of which $1.7 million was incurred through March 31, 2012.

General and administrative expenses increased to $3.2 million in the first quarter of 2012 as compared to $2.8 million for the same period in 2011, due primarily to non-cash expenses associated with the company’s new office facility and higher professional fees.

As of March 31, 2012, the company had $20.7 million in cash and cash equivalents and short-term investments compared to $18.3 million as of December 31, 2011. Net cash used in operating activities for the first quarter of 2012 was $4.2 million compared to $9.0 million for the same period in 2011, a 53% reduction from the prior year due primarily to revenue under the HHS BARDA contract.

Key Highlights during the First Quarter of 2012:

• Launched a Phase II dose-ranging clinical trial of the company’s trivalent and quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidates in Australia. The trial will evaluate the immunogenicity and safety of three dose levels of the company’s seasonal recombinant VLP influenza vaccine candidates in healthy adults between the ages of 18 and 64.
• Presented positive results from a Phase I trial of the company’s recombinant nanoparticle vaccine candidate against respiratory syncytial virus (RSV) at the XIV International Symposium on Viral Infections. Findings from this Phase I trial are consistent with pre-clinical results in relevant animal models, which indicated that the company’s vaccine candidate was generally well-tolerated, highly immunogenic and produced functional antibodies that neutralized RSV.
• Reported manufacturing progress and preparations to begin clinical testing of influenza and rabies vaccines under the company’s joint venture in India with Cadila Pharmaceuticals. Rabies is the largest selling vaccine in India and China is the largest market with 12-15 million vaccine doses annually; and
• Expanded the company’s senior management team with the appointments of John Herrmann III as Vice President and General Counsel and Mervyn Hamer as Vice President of Manufacturing.

“The first quarter was a very productive period for our company as we launched a Phase II trial of our seasonal influenza vaccine candidates and reported the very encouraging, positive results from our Phase I RSV trial,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “The Phase II seasonal influenza vaccine trial is particularly important because we expect that it will help us establish the immunogenicity, safety and tolerability of our quadrivalent seasonal influenza VLP vaccine candidate. The data resulting from this trial will aid in determining the most effective and appropriate dose for evaluation in our upcoming Phase IIb dose-confirmatory trial and ultimately in our Phase III registration trial. In addition, the data from our Phase I RSV trial continues to drive interest among potential partners for this important disease target. We expect to launch two RSV clinical trials in both the elderly and women-of-child bearing-age populations in the second half of 2012.”

Conference Call

Novavax’s management will host its quarterly conference call today at 10:00 a.m. EDT. The live conference call will be accessible on Novavax’s website at www.novavax.com under “Investor Info/Events” or by telephone at 1 (877) 212-6076 (Domestic) or 1 (707) 287-9331 (International). A replay of the webcast will be available on the Novavax website for 60 days after the call and a replay of the conference call will be available beginning today at 1:00 pm through July 04, 2012. To access the replay of the conference call, dial 1 (855) 859-2056 (Domestic) or 1 (404) 537-3406 (International) and enter passcode 76044510.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces potent vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company’s website, www.novavax.com.

Forward Looking Statements

Statements herein relating to the future of Novavax and its ongoing development of its vaccine products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, that may cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2011, and filed with the Securities and Exchange Commission. Novavax cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. Investors, potential investors, and others should give careful consideration to risks and uncertainties and are encouraged to read Novavax filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and Novavax undertake no obligation to update or revise any of the statements.

CONTACT: Frederick W. Driscoll
         VP, Chief Financial Officer and Treasurer
         Novavax, Inc.
         240-268-2000

Real Goods Solar (RSOL) Engages Liolios Group to Lead Investor Relations Program

LOUISVILLE, Colo., May 2, 2012 (GLOBE NEWSWIRE) — Real Goods Solar, Inc. (Nasdaq:RSOL), a leading provider of turnkey commercial and residential solar energy solutions, has engaged Liolios Group to lead a new investor relations and financial communications program.

“We have arrived at a major inflection point in our growth, demonstrated by record revenue and solid cash flow in 2011, and supported by the Alteris acquisition that has dramatically increased our economy of scale and national presence,” stated Bill Yearsley, Real Goods Solar’s chief executive officer. “With this stronger foundation in place, we believe our company and its shareholders would benefit from the experienced IR professionals at Liolios Group.”

In collaboration with Real Goods Solar management, Liolios Group will refine and deliver the company’s message to the financial community. Liolios Group will also schedule a number of one-on-one conference calls, road shows and financial conferences that will engage key influencers, such as equity analysts, institutional investors and members of the financial press.

For more information about Real Goods Solar, contact Liolios Group at 1-949-574-3860 or email RSOL@liolios.com.

About Liolios Group, Inc.

Liolios Group, Inc. is a strategic financial communications firm focused on small-cap companies across a broad range of industry classifications. Liolios Group aims to deliver superior performance in corporate messaging and positioning, investor awareness, analyst and financial press coverage, and capital attraction. Founded in 1999, Liolios Group executives have extensive experience in finance and investments, and have represented more than 125 global companies in a wide range of industries. For more information about Liolios Group, go to www.liolios.com.

About Real Goods Solar, Inc.

Real Goods Solar, Inc. (Nasdaq:RSOL) is a leading provider of turnkey commercial and residential solar energy solutions, with more than 13,000 solar systems in place. Real Goods Solar has more than 33 years of experience in solar energy, beginning with the sale in 1978 of the first solar photovoltaic panels in the United States. With 16 offices across the West and the Northeast, Real Goods Solar is one of the largest solar energy installers in the U.S. For more information about Real Goods Solar, please visit www.realgoodssolar.com, or call (888) 507-2561.

The Real Goods Solar, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6455

CONTACT: Company Contact:
         John Coletta
         Chief Financial Officer
         Real Goods Solar, Inc.
         Tel (303) 222-8310
         john.coletta@realgoods.com

         Investor Relations:
         Ron Both
         Liolios Group, Inc.
         Tel (949) 574-3860
         RSOL@liolios.com

PURE Bioscience (PURE) Hard Surface Showcased at National Restaurant Association Show 2012

PURE Bioscience, Inc. (NASDAQ:PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Intercon Chemical Company is showcasing the PURE Complete System in conjunction with its Clearly Better Solutions product line at this year’s National Restaurant Association Show, May 5-8 at McCormick Place in Chicago (booth number 1085). The annual NRA Show draws more than 58,000 restaurant and food service industry professionals from all 50 states and more than 100 countries, and presents the newest innovations and latest information on trends and issues.

The PURE Complete System product line includes PURE Hard Surface disinfectant and food contact surface sanitizer, PURE Multi-Purpose Cleaner Concentrate and PURE Floor Cleaner Concentrate.

Jim Epstein, President of Intercon, stated, “The NRA Show is an excellent venue to present PURE Hard Surface, as restaurants bear tremendous responsibility for national food safety. Americans are spending more time and money each year eating away from home, and studies show that at least 50% of foodborne disease outbreaks can be attributed to restaurants. We know that disinfection and food contact surface sanitization is a key element of pathogen control in restaurants because bacteria and viruses survive on, and can contaminate, hard surfaces such as counters, door handles, appliances, tables, chairs and trays. Restaurants can be confident that PURE Hard Surface quickly stops the contamination cycle.”

Tom Myers, PURE Bioscience’s Executive Vice President, Sales and Marketing, added, “Even just one outbreak of foodborne illness can have devastating effects on a business, and Intercon’s presentation of the benefits of implementing PURE Hard Surface will resonate with distributors and customers. The quick kill times of PURE’s low-toxicity and odorless formula, along with SDC’s GRAS status as a contact biocide, set PURE apart from toxic chemicals currently used in restaurants. PURE Hard Surface is an ideal choice to meet the health and business challenges of food safety in the restaurant industry.”

About the PURE Complete Cleaning, Sanitizing and Disinfecting System

US EPA registered PURE Hard Surface disinfectant and food contact surface sanitizer provides an unparalleled combination of high efficacy and low toxicity with 30-second bacterial and viral kill times and 24-hour residual protection. SDC-based PURE Hard Surface completely kills resistant pathogens like MRSA and Carbapenem-resistant Klebsiella pneumoniae (NDM-1) and also effectively eliminates dangerous fungi and viruses including HIV, Hepatitis B, Hepatitis C, Norovirus, Influenza A, Avian Influenza and H1N1 as well as hazardous food pathogens such as E. coli, Salmonella and Campylobacter. PURE Hard Surface delivers powerful broad-spectrum efficacy while remaining classified as least-toxic (Category IV) by the US EPA, and its active ingredient, SDC, has been determined Generally Recognized as Safe (GRAS) for use as a biocide on food processing equipment, machinery and utensils.

PURE’s Multi-Purpose Cleaner and Floor Cleaner concentrates are non-toxic, environmentally responsible cleaning products protected by SDC, a natural, non-toxic antimicrobial. SDC ensures the quality and safety of PURE Floor Cleaner and PURE Multi-Purpose Cleaner without human or environmental exposure to toxic chemical preservatives. PURE Floor Cleaner and PURE Multi-Purpose cleaner are non-flammable and contain no EDTA, phosphates, ammonia or bleach as well as no VOCs or NPEs. PURE Floor Cleaner and PURE Multi-Purpose Cleaner provide professional strength cleaning in a concentrate formula that yields a 1:128 use dilution that is safe for use on all resilient surfaces. The PURE Complete system strengthens infection control and sustainability programs while providing a cost-effective and user-friendly solution.

About Intercon Chemical Company and Clearly Better Solutions.

Privately owned Intercon Chemical Company in St. Louis, Missouri, employees more than 150 people at its 250,000 square foot FDA and EPA-registered cGMP compliant manufacturing facility. Intercon has operated for more than 30 years in the cleaning and sanitation chemical manufacturing and service industries with expertise in formulating, manufacturing and marketing liquids, powders and solids as well as packaging and labeling. Intercon provides state-of-the-art chemical products and programs to its network of distributors in multiple markets, including: facility management companies, janitorial supply companies, food service sanitation, healthcare and infection control, commercial floor care, critical process cleaning, food processing facility maintenance, institutional laundry, contract packaging and green products. For more information about Intercon Chemical Company, please visit www.interconchemical.com. Intercon’s Clearly Better brand products and programs are designed to bring breakthrough cleaning, disinfection, sanitization, skin care, air treatment and odor control technologies to market that offer innovative solutions to solve problems not adequately addressed by current options. Clearly Better offers programs under its Smart Drains, Smart Floors, Smart Air, Clearly Better Scents and Clearly Better Medical brands. More information is available at www.clearlybetter.com.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, the Company’s failure to implement or otherwise achieve the benefits of its strategic initiatives, acceptance of the Company’s current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Digital Ally, Inc. (DGLY) Schedules Investor Conference Call to Discuss First Quarter 2012 Operating Results

OVERLAND PARK, KS — (Marketwire) — 05/04/12 — Digital Ally, Inc. (NASDAQ: DGLY), which develops, manufactures and markets advanced digital technology products for law enforcement, homeland security and commercial security applications, today announced that the Company will host an investor conference call on Friday, May 11, 2012 at 11:15 a.m. Eastern Time to discuss its operating results for the first quarter of 2012, along with other topics of interest. The Company will release its operating results in a press release after the market closes on Thursday, May 10, 2012.

Shareholders and other interested parties may participate in the conference call by dialing 877-317-6789 (international/local participants dial 412-317-6789) and asking to be connected to the “Digital Ally, Inc. Conference Call” a few minutes before 11:15 a.m. EDT on May 11, 2012.

A replay of the conference call will be available one hour after the completion of the conference call from May 11, 2012 until 9:00 a.m. on July 10, 2012 by dialing 877-344-7529 (international/local participants dial 412-317-0088) and entering the conference ID# 10013728.

About Digital Ally, Inc.

Digital Ally, Inc. develops, manufactures and markets advanced technology products for law enforcement, homeland security and commercial applications. The Company’s primary focus is digital video imaging and storage. For additional information, visit www.digitalallyinc.com

The Company is headquartered in Overland Park, Kansas, and its shares are traded on The Nasdaq Capital Market under the symbol “DGLY”.

For Additional Information, Please Contact:
Stanton E. Ross
CEO
(913) 814-7774
or
RJ Falkner & Company, Inc.
Investor Relations Counsel
(800) 377-9893
or via email at info@rjfalkner.com